

SELECTED PUBLICATIONS AND PRESENTATIONS

PEER REVIEWED PUBLICATIONS

1. Peechatka A Gerzon M, Ly JJ, Dallabrida SM. Oncology patient preferences in reporting on symptoms. *Int J Clin Trials*. 2020;7(1):11-17
2. Dias N, Howley A, Yamamoto R, Dallabrida SM. Training Subjects on Key Concepts from Patient-Reported Outcomes (PROs) Improves Understanding & Data Accuracy. *Patient Relat Outcome Meas*. 2019;10:315-319 (high volume views)
3. Ly JJ, Crescioni M, Eremenco S, Bodart S, Donoso M, Butler AJ, Dallabrida SM. Training on the Use of Technology to Collect Patient-Reported Outcome Data Electronically in Clinical Trials: Best Practice Recommendations from the ePRO Consortium. *Ther Innov Regul Sci*. 2019;53(4):431-440
4. Miklas JW, Dallabrida SM, Reis LA, Ismail N, Rupnick M, Radisic M. QHREDGS enhances tube formation, cell metabolism and survival of endothelial cells in collagen-chitosan hydrogels. *PLoS One*. 2013;8(8):e72956
5. Brem Sunshine S, Dallabrida SM, Durand EM, Ismail NS, Bazinet L, Birsner A, Ryeom S, Sohn R, Ikeda S, Pu W, Liao R, Kulke M, Javaherian K, Zurakowski D, Folkman J, Rupnick MA. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. *Proc Natl Acad Sci USA*, 2012; 109(28):11306
6. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. *Hypertension*, 2011; 58:85-92
7. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Incidence & risk of congestive heart failure in patients treated with renal & non renal cell carcinoma treated with sunitinib. *J Clin Oncol* 2011; 29:3450-3456
8. Rask F, Dallabrida SM, Ismail NI, Amoozgar Z, Yeo Y, Rupnick M, Radisic M, Photocrosslinkable chitosan-modified with angiopoietin-1 peptide, promotes survival of neonatal rat heart cells. *J Biomedical Mat. Res*. 2010; 95(1):105-17

9. Rask F, Mihic A, Reis L, Dallabrida SM, Ismail NI, Sider K, Simmons CA, Rupnick MA, Weisel RD, Li R-K, Radisic M. Hydrogels modified with QHREDGS peptide support cardiomyocyte survival in vitro and after sub-cutaneous implantation. *Soft Matter, Special Tissue Engineering Issue*. 2010; 6, 5089-5099
10. Dallabrida SM, Ismail NS, Pravda EA, Parodi EM, Dickie R, Durand EM, Lai J, Cassiola F, Rogers RA, Rupnick MA. Integrin Binding Angiopoietin-1 Monomers Reduce Cardiac Hypertrophy. *FASEB J*. 2008;22:3010-23
11. Ferreira LS, Gerecht S, Shieh HF, Watson N, Rupnick MA, Dallabrida SM, Vunjak-Novakovic G, Langer R. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle-like cells and form vascular networks in vivo. *Circ Res*. 2007;3:101:286-94.
12. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007;370:2011-9
13. Dickie R, Bachoo RM, Rupnick MA, Dallabrida SM, DeLoid GM, Lai J, DePinho RA, Rogers RA. Three-dimensional visualization of microvessel architecture of whole-mount tissue by confocal microscopy. *Microvas. Res*. 2006;72:20-26
14. Dallabrida SM, Ismail N, Oberle JO, Himes BZ, Rupnick MA. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. *Circ Res*. 2005;96:e8-e24 (Ultrarapid Communication)

CONFERENCE PRESENTATIONS

1. Ly, J, Heidman M, Dallabrida SM, Digital Enrollment and Communication Acceptance for Decentralized Clinical Trial Participation, ISPOR 2023
2. Ly, J, Heidman M, Dallabrida SM, Technology and Device Acceptance Among an Older Population for Decentralized Clinical Trial Participation, ISPOR 2023
3. Ly, J, Heidman M, Dallabrida SM, Decentralized Clinical Trials and Time Burden: Important Considerations for Potential Clinical Trial Participants, ISPOR 2023
4. Dallabrida SM, Heidman M and Ly J. Demystifying Innovative Assessment Methods for Patients, Communities, and Research Participants in Psychooncology, APOS Symposium March 15-17, 2023, Portland, Oregon
5. Heidman, M, Culbreth-Notaro M, Raymond E, Bartels C, Dallabrida SM. Obvio-19 App Ease of Use of Cancer Patients for Reporting COVID-19 Symptomology (ONCOVID Study), ISPOR, Vienna, Austria, 2022

6. Heidman, M, Brenner, D, Dallabrida SM. Methods for Elderly Blood Draw Participant Recruitment, ISPOR, Vienna, Austria, 2022
7. Heidman, M, Brenner, D, Dallabrida SM. Methods for Elderly Colonoscopy Naïve Participant Recruitment, ISPOR, Vienna, Austria, 2022
8. Dallabrida SM and Culbreth-Notaro M., Use of Social Media Based in Decentralized Clinical Trials: Impact on Age of Recruitment, DIA, 2022
9. Dallabrida SM and Culbreth-Notaro M., Meta-Analysis: ePRO Compliance and Retention for Patients using their own Smartphones in Fully Decentralized Clinical Trials ISPOR, 2022
10. Dallabrida SM, Guo G, Parth S, Linke H, Culbreth-Notaro M. Age Does Not Impact Patient Ease of Use for Recording Their COVID-19 Symptoms in an Electronic Capture Diary: Results from the Obvio-19 Study, Virtual DIA, 2021
11. Dallabrida SM, Parth S, Linke H, Culbreth-Notaro M. Patient Preferences and Feedback Regarding Daily Reporting of COVID-19 Symptoms using Personal Smartphones for the Obvio-19 Study, Virtual ISPOR, 2021
12. Dallabrida SM, Guo G, Culbreth-Notaro M. Compliance with ePRO is High and Stable with Patients using their own Smartphones in Fully Decentralized Clinical Trials, Virtual ISPOR, 2021
13. Dallabrida SM, Current landscape and potential for driving efficiencies via Virtual Trial Solutions in Asia Pacific, Oncology Clinical Trials, Boston, MA, 2021
14. Peechatka AL, Gerzon M, Dallabrida SM, Breast Cancer Patient Perspectives on Important Symptom Information, ISPOR Europe, Copenhagen, Denmark, 2019
15. Dumais K, Dallabrida SM, Patient Understanding of Rescue Medication: Value of Patient Training on Reporting Rescue Medication Use, DIA Annual Meeting, San Diego, CA, 2019
16. Ly JJ, Yamamoto R, Tuller JM, Dias N, Dallabrida SM, A Patients with Cancer View Physical Symptoms and Impact of Symptoms as Important Information to Provide Healthcare Providers on A Daily Basis, ISPOR Latin America, Bogotá, Colombia, 2019
17. Conrad ES, Dallabrida SM, Subject Training Is Needed for Key Terminology in Oncology Clinical Trials ISPOR Latin America, Bogotá, Colombia, 2019
18. Yamamoto R, Dallabrida SM, Cancer Patients Prefer Reporting Symptoms in Daily Electronic Diaries at Home, ISPOR Latin America, Bogotá, Colombia, 2019
19. Dumais K, Dallabrida SM, A Patient Misunderstanding of How to Report Pain and Swelling, CNS Summit, Boca Raton, FL, 2019

20. Howley AR, Dias N, Arnera V, Dallabrida SM, Training Improves Patient Understanding of Complex PRO Terminology: Nausea and Vomiting, International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, Copenhagen, Denmark, 2019
21. Ly JJ, Dias N, Tuller JM, Dallabrida SM, Patients with Chronic Pain Disorders: Preference Of ePRO Screen Display and Features, ISPOR Europe, Copenhagen, Denmark, 2019
22. Dumais K, Dallabrida SM, Patient Understanding of Rescue Medication: Value of Patient Training on Reporting Rescue Medication Use, Society for Neuroscience 49th Annual Meeting, Chicago, IL, 2019
23. Yamamoto RT, Dallabrida SM, Common Symptom Terminology Is Frequently Misunderstood, DIA Annual Meeting, San Diego, CA, 2019
24. Gauthier M, Egan S, Ryan A, Khurana L, Dallabrida SM, Evans C, Do Words Matter? Patient Perspectives on Conceptually Similar Symptoms and Impacts Frequently Utilized in Patient-Reported Outcome (PRO) Measures, ISPOR, Baltimore, MD, 2018
25. Dallabrida SM, Why the increased use of electronic patient-reported outcomes (PROs) and other clinical outcomes assessments (COAs) in oncology studies?, Clinical Operations in Oncology Trials East Coast, Boston, MA, 2018
26. Dallabrida SM, Why the increased use of electronic patient-reported outcomes (PROs) and other clinical outcomes assessments (COAs) in oncology studies?, Clinical Operations in Oncology Trials West Coast, 2018
27. Yamamoto RT, Durand E, Gary S, Tuller JM, Dallabrida SM, Patient Reported Outcomes (Pros) Are Subject to Interpretation Errors: Patients' Understanding of How to Report Pain Severity Over A Period of Time, ISPOR 22nd International Annual Meeting, Boston, 2017
28. Ly JJ, Durand E, Gary S, Tuller JM, Dallabrida SM, Patients Consider Training A Necessary Part of Clinical Trials, Preferring Readily-Accessible Interactive Electronic Training, ISPOR 22nd International Annual Meeting, Boston, 2017
29. Evans CJ, Serrano D, Witherspoon B, Khurana L, Dallabrida SM, Are Patient's Responses to Five Point Verbal Descriptor Scales and Visual Analogue Scales
30. Evans CJ, Serrano D, Witherspoon B, Khurana L, Dallabrida SM, Pain Assessment: A Myriad of Techniques to Measure Pain Severity Does it Matter Which One is Used?, ISPOR 22nd International Annual Meeting, Boston, 2017
31. Tutuncu A, Egan S, Evans C, Cala ML, Ryan A, Khurana L, Dallabrida SM, Proximal Versus Distal Impacts of Disease: Drivers of Botheredness Ratings in Patient-Reported Outcome (PRO) Studies, ISPOR 22nd International Annual Meeting, Boston, 2017

32. Tutuncu A, Egan S, Evans C, Ryan A, Cala ML, Khurana L, Dallabrida SM, What is Being Measured in Patient-Reported Outcome (PRO) Measures? Symptom Questions May Often Reveal Impact Answers, ISPOR 22nd International Annual Meeting, Boston,
33. Khurana L, Durand EM, Gary ST, Otero AV, Hall C, Ryan A, Evans CJ, Dallabrida SM, Patient Preference for Display of Electronic Patient-Reported Outcomes: Wording Emphasis, Question Format, and Navigation Button Placement, ISPOR, Washington, DC, 2016
34. Khurana L, Durand EM, Gary ST, Otero AV, Hall C, Ryan A, Evans CJ, Dallabrida SM, Patient Preference for Using Computers, Smartphones, And Internet to Participate in Clinical Trials, ISPOR, Washington, DC, 2016
35. Gary ST, Otero AV, Dallabrida SM. Effective use of electronic patient reported outcomes (ePRO) in breast cancer, European Cancer Congress, Amsterdam, 2013
36. Dallabrida SM, Arnera V, Raymond S. Effective Use of Electronic Patient Reported Outcomes (ePROs) in Oncology. DIA 25th EuroMeeting, Amsterdam, 2013
37. Dallabrida SM, Oncology Clinical Outcome Assessments & Patient-Reported Outcomes, Effective Use, Analysis and Best Practices of eCOA Data Capture for COPD Research Birds of a Weather Forum, 2013
38. Dallabrida SM, Adult Oncology: Clinical Outcome Assessments (COAs) & Patient-Reported Outcomes (PROs), DIA Webinar 2012